Longer-lasting Botox competitor nabs FDA approval — can it compete with AbbVie's $2B cash cow?

Revance Therapeutics announced Thursday that its first FDA approval has finally arrived for its Botox competitor, known as Daxxify, after initially submitting its original BLA way back in January 2020.